New Strategies Sought to Pay for Costly Cures

As Congressional leaders and White House policymakers assess a range of measures designed to manage or reduce outlays for prescription drugs, pharma companies and other stakeholders are weighing innovative reimbursement models for new therapies promising to cure or treat serious illnesses. Payer Powered by WPeMatico Continue reading New Strategies Sought to Pay for Costly Cures

8 Tipping Points: Pharm Exec s 2019 Industry Forecast

Welcome once again to Pharm Exec s annual look at what s ahead for the biopharma industry, where we hope the eight trends singled out for this year capture the pulse of change and opportunity impacting leaders and decision-makers in the life sciences the most. From technology and digital hea Powered by WPeMatico Continue reading 8 Tipping Points: Pharm Exec s 2019 Industry Forecast

Securing a Winning Strategy for Real-World Evidence

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by biopharma companies to embed and secure an RWE capability effectively across the organization is still a work in progress In Deloitte s Second Annual Real-World Powered by WPeMatico Continue reading Securing a Winning Strategy for Real-World Evidence

Piecing Together the Pricing Puzzle: The Midterm Elections

There is no magic bullet that will dramatically impact drug pricing to everybody s liking patients, industry, and government. But a stepwise approach involving a series of changes, including taking advantage of the next midterm elections, could point the path toward a solution Powered by WPeMatico Continue reading Piecing Together the Pricing Puzzle: The Midterm Elections